Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | NEK7 | Q8TDX7 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4189874 | 0.80 | KDM4E (0.43) | KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4192376 | 0.79 | KMT2A (0.42) | KMT2AEPHX2F2RL1MAPK14SMN1; SMN2 | |
| SCHEMBL4196799 | 0.76 | CCR3 (0.50) | KMT2AEPHX2SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL4197445 | 0.76 | KMT2A (0.48) | KMT2AF2RL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4195095 | 0.76 | KMT2A (0.48) | KMT2AF2RL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4196629 | 0.76 | KMT2A (0.48) | KMT2AF2RL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4192548 | 0.75 | KMT2A (0.47) | KMT2AEPHX2F2RL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4186522 | 0.74 | GCK (0.48) | KMT2AEPHX2 | |
| SCHEMBL4196843 | 0.73 | EPHX1 (0.52) | KMT2AALDH1A1RAB9A | |
| SCHEMBL4193053 | 0.73 | TP53 (0.52) | KMT2AF2RL1SMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | claimed |
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | claimed |
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | disclosed |
| US-8076370-B2 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2011-12-13 | — | — | US | disclosed |
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215764-A1 | Antimicrobial agents | TUFM, RPS17, HARS1 | IDO1 2382/4885KMT2A 2047/4885EPHX2 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.